Adalimumab as a cause of kidney injury in patients with Crohn’s disease
Pediatric Nephrology · 2024
DOI: 10.1007/s00467-024-06338-0 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Nephrology, 2024. Verfasst von Krzysztof Skoczyński und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland. Hauptthemen laut MEDLINE: Acute Kidney Injury, Adalimumab, Crohn Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI). CASE DIAGNOSIS/TREATMENT: We describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function. CONCLUSIONS: Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland.
- Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.
- Department of Pathology, The Children`s Memorial Health Institute, Warsaw, Poland.
- Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland. m.litwin@ipczd.pl.
- Chair of Pediatric Nephrology, The Center of Continuing Medical Education, Warsaw, Poland. m.litwin@ipczd.pl.
ORCID-Profile: Mieczysław Litwin
Zitieren
APA
Skoczyński, K., Koziej, J., Szymańska, S., Obrycki, Ł., Grenda, R., & Litwin, M. (2024). Adalimumab as a cause of kidney injury in patients with Crohn’s disease. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06338-0
Vancouver
Skoczyński K, Koziej J, Szymańska S, Obrycki Ł, Grenda R, Litwin M. Adalimumab as a cause of kidney injury in patients with Crohn’s disease. Pediatric Nephrology. 2024. doi:10.1007/s00467-024-06338-0
BibTeX
@article{Skoczyski2024,
author = {Skoczyński, Krzysztof and Koziej, Jan and Szymańska, Sylwia and Obrycki, Łukasz and Grenda, Ryszard and Litwin, Mieczysław},
title = {Adalimumab as a cause of kidney injury in patients with Crohn’s disease},
journal = {Pediatric Nephrology},
year = {2024},
doi = {10.1007/s00467-024-06338-0}
}
EUVIMED